Malaria drug tested as hope for kids with fatal genetic lung conditions
NCT ID NCT04532346
Summary
This study is testing whether hydroxychloroquine, a medication used for malaria and autoimmune diseases, can help children with rare genetic lung disorders breathe easier. Researchers will compare children who receive the drug to those who don't to see if it improves oxygen levels and reduces breathing problems. The trial includes 60 children under 18 who have specific genetic mutations affecting their lungs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201102, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.